Bio-Techne (TECH) Form 4 BIO-TECHNE / Charles R. Kummeth ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Kummeth Charles R.

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2019

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2019		A		11,291	A	$0	103,467(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$67.46							(2)	04/01/2020	Common Stock	65,000		65,000	D
Stock Options (Right to Buy)	$86.25							(2)	04/01/2021	Common Stock	46,316		46,316	D
Stock Options (Right to Buy)	$94.35							(2)	08/12/2021	Common Stock	66,849		66,849	D
Stock Options (Right to Buy)	$108.49							(2)	08/07/2022	Common Stock	79,517		79,517	D
Restricted Stock Units	(3)							(4)	(4)	Common Stock	24,979		24,979	D
Stock Options (Right to Buy)	$106.59							(4)	08/18/2023	Common Stock	154,169		154,169	D
Stock Options (Right to Buy)	$106.59							(5)	08/18/2023	Common Stock	102,779		102,779	D
Restricted Stock Units	(3)							(6)	(6)	Common Stock	21,291		21,291	D
Stock Options (Right to Buy)	$125.05							(6)	08/09/2024	Common Stock	117,342		117,342	D
Stock Options (Right to Buy)	$125.05							(7)	08/09/2024	Common Stock	78,228		78,228	D
Restricted Stock Units	(3)							(8)	(8)	Common Stock	16,918		16,918	D
Stock Options (Right to Buy)	$177.32							(8)	08/08/2025	Common Stock	90,334		90,334	D
Stock Options (Right to Buy)	$177.32							(9)	08/08/2025	Common Stock	60,222		60,222	D
Restricted Stock Units	(3)	08/07/2019		A		16,937		(10)	(10)	Common Stock	16,937	$0	16,937	D
Stock Options (Right to Buy)	$190.41	08/07/2019		A		85,725		(10)	08/07/2026	Common Stock	85,725	$0	85,725	D
Stock Options (Right to Buy)	$190.41	08/07/2019		A		57,150		(11)	08/07/2026	Common Stock	57,150	$0	57,150	D

Explanation of Responses:

1. Includes (i) 5,551 shares of restricted stock for which the risk of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risk of forfeiture will lapse with repect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iv) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022.

2. Fully exercisable.

3. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

4. Vests in full or in part on 8/18/2019 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

5. Options to purchase 25,695 shares vest on each of 8/18/2017, 8/18/2018 and 8/18/2019 and options to purchase 25,695 shares vest on 8/18/2020.

6. Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

7. Options to purchase 19,557 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021.

8. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

9. Options to purchase 15,056 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 15,055 shares vest on each of 8/8/2021 and 8/8/2022.

10. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

11. Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023.

Remarks:

	/s/ Brenda S. Furlow as Attorney-in-Fact for Charles R. Kummeth pursuant to Power of Attorney previously filed.	08/09/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.